Castle Biosciences to Present at Upcoming Investor Conferences
-
Credit Suisse 31st Annual Healthcare Conference on
Nov. 9, 2022 , at12:50 p.m. Eastern time . -
Stephens Annual
Investment Conference onNov. 16, 2022 , at11:00 a.m. Eastern time . -
Canaccord Genuity (CG)
MedTech , Diagnostics andDigital Health & Services Forum onNov. 17, 2022 , at11:30 a.m. Eastern time .
Live audio webcasts of the Company’s presentations will be available on Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. Replays of the webcasts will be available following the conclusion of the broadcasts.
About
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005141/en/
Investor Contact:
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: